EUVIMEDEUVIMED entdecken
Open Access

Antibody/ siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem‐Like Behavior in Triple‐Negative Breast Cancer Cells

Elise C Hoover iD, Emily S Day iD

Journal of Biomedical Materials Research Part A · 2025

DOI: 10.1002/jbm.a.37867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, 2025. Verfasst von Elise C Hoover und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Delaware, Newark, Delaware, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Wnt Signaling Pathway, Nanoparticles, RNA, Small Interfering. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) is infamous for its aggressive phenotype and poorer prognosis when compared to other breast cancer subtypes. One factor contributing to this poor prognosis is that TNBC lacks expression of the receptors that available hormonal or molecular‐oriented therapies attack. New treatments that exploit biological targets specific to TNBC are desperately needed to improve patient outcomes. One promising target for therapeutic manipulation is the Wnt signaling pathway, which has been associated with many invasive breast cancers, including TNBC. This pathway is activated in TNBC cells when extracellular Wnt ligands bind to overexpressed Frizzled7 (FZD7) transmembrane receptors, leading to downstream activation of intracellular β‐catenin proteins. To target and inhibit Wnt signaling in TNBC cells, polymer nanoparticles (NPs) modified with anti‐FZD7 antibodies and β‐catenin small interfering RNAs (siRNAs) were developed, and their impact on the oncogenic behavior of treated TNBC cells was investigated. When compared to control NPs, the Wnt‐targeted NPs induced greater levels of Wnt oncogene suppression. This led to greater inhibition of oncogenic and stem‐like properties, including cell proliferation, drug resistance, and spheroid formation capacity. This work demonstrates a promising approach for targeting the Wnt pathway in TNBC to counter the cellular phenotypes that drive disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsWnt Signaling PathwayNanoparticlesRNA, Small InterferingFrizzled ReceptorsHumansCell Line, TumorNeoplastic Stem CellsFemaleAntibodiesbeta CateninDrug Carriers

Stichwörter der Autor:innen

Frizzled7RNA interferenceantibodiesnanomedicineoncologytargeted therapyβ‐catenin

Substanzen

RNA, Small InterferingFrizzled ReceptorsFZD7 protein, humanAntibodiesbeta CateninDrug Carriers

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Delaware, Newark, Delaware, USA.
  • Department of Materials Science and Engineering, University of Delaware, Newark, Delaware, USA.
  • Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, Newark, Delaware, USA.

ORCID-Profile: Elise C Hoover, Emily S Day

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Hoover, E. C., & Day, E. S. (2025). Antibody/ siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem‐Like Behavior in Triple‐Negative Breast Cancer Cells. Journal of Biomedical Materials Research Part A. https://doi.org/10.1002/jbm.a.37867

Vancouver

Hoover EC, Day ES. Antibody/ siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem‐Like Behavior in Triple‐Negative Breast Cancer Cells. Journal of Biomedical Materials Research Part A. 2025. doi:10.1002/jbm.a.37867

BibTeX
@article{Hoover2025,
  author = {Hoover, Elise C and Day, Emily S},
  title = {Antibody/ siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem‐Like Behavior in Triple‐Negative Breast Cancer Cells},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2025},
  doi = {10.1002/jbm.a.37867}
}
Kostenlos starten →